
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its ...
Study conducted at The Massachusetts General Hospital’s Vaccine and Immunotherapy Center demonstrated highly significant improvements in Overall Survival and other key endpoints VTX-0P4, in combination with a CPI, had a statistically significant …